BRIEF-ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05
Reuters2026/08/07 10:51Aug 07 (Reuters) - ANI Pharmaceuticals Q2 adjusted EBITDA USD 71.6 million.
- Q2 EPS USD 1.05
- Q2 net income USD 24.7 million
- outlook FY adjusted EBITDA USD 285-300 million
- outlook FY revenue USD 1,080-1,140 million vs. IBES estimate USD 1,119 million
- outlook FY adjusted EPS USD 9.19-9.69 vs. IBES estimate USD 9.45
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
